Annual EBITDA
-$29.74 M
-$3.79 M-14.60%
31 December 2023
Summary:
INmune Bio annual earnings before interest, taxes, depreciation & amortization is currently -$29.74 million, with the most recent change of -$3.79 million (-14.60%) on 31 December 2023. During the last 3 years, it has fallen by -$17.51 million (-143.22%). INMB annual EBITDA is now -12972.97% below its all-time high of -$227.50 thousand, reached on 31 December 2016.INMB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$12.29 M
-$2.42 M-24.54%
30 September 2024
Summary:
INmune Bio quarterly earnings before interest, taxes, depreciation & amortization is currently -$12.29 million, with the most recent change of -$2.42 million (-24.54%) on 30 September 2024. Over the past year, it has dropped by -$3.76 million (-44.07%). INMB quarterly EBITDA is now -3895.45% below its all-time high of -$307.50 thousand, reached on 30 September 2017.INMB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$41.55 M
-$3.76 M-9.94%
30 September 2024
Summary:
INmune Bio TTM earnings before interest, taxes, depreciation & amortization is currently -$41.55 million, with the most recent change of -$3.76 million (-9.94%) on 30 September 2024. Over the past year, it has dropped by -$14.54 million (-53.85%). INMB TTM EBITDA is now -13411.22% below its all-time high of -$307.50 thousand, reached on 30 September 2017.INMB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INMB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.6% | -44.1% | -53.9% |
| 3 y3 years | -143.2% | -36.2% | -78.1% |
| 5 y5 years | -139.1% | -298.4% | -369.7% |
INMB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -143.2% | at low | -117.8% | at low | -78.1% | at low |
| 5 y | 5 years | -219.9% | at low | -487.3% | at low | -369.7% | at low |
| alltime | all time | <-9999.0% | at low | -3895.4% | at low | <-9999.0% | at low |
INmune Bio EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.29 M(+24.5%) | -$41.55 M(+9.9%) |
| June 2024 | - | -$9.87 M(-10.5%) | -$37.79 M(+10.1%) |
| Mar 2024 | - | -$11.02 M(+31.5%) | -$34.34 M(+15.4%) |
| Dec 2023 | -$29.74 M(+14.6%) | -$8.38 M(-1.7%) | -$29.74 M(+10.1%) |
| Sept 2023 | - | -$8.53 M(+33.0%) | -$27.00 M(+4.2%) |
| June 2023 | - | -$6.41 M(-0.2%) | -$25.92 M(+0.1%) |
| Mar 2023 | - | -$6.42 M(+13.8%) | -$25.90 M(-0.2%) |
| Dec 2022 | -$25.95 M(-11.0%) | -$5.64 M(-24.2%) | -$25.95 M(-11.5%) |
| Sept 2022 | - | -$7.44 M(+16.5%) | -$29.34 M(-5.1%) |
| June 2022 | - | -$6.39 M(-1.4%) | -$30.92 M(-0.5%) |
| Mar 2022 | - | -$6.48 M(-28.3%) | -$31.08 M(+6.6%) |
| Dec 2021 | -$29.15 M(+138.4%) | -$9.03 M(+0.1%) | -$29.15 M(+24.9%) |
| Sept 2021 | - | -$9.02 M(+37.6%) | -$23.33 M(+22.0%) |
| June 2021 | - | -$6.55 M(+44.1%) | -$19.13 M(+30.3%) |
| Mar 2021 | - | -$4.55 M(+41.7%) | -$14.68 M(+20.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$12.23 M(+31.5%) | -$3.21 M(-33.4%) | -$12.23 M(+7.7%) |
| Sept 2020 | - | -$4.82 M(+128.8%) | -$11.35 M(+18.1%) |
| June 2020 | - | -$2.11 M(+0.7%) | -$9.62 M(+1.4%) |
| Mar 2020 | - | -$2.09 M(-10.3%) | -$9.48 M(+1.9%) |
| Dec 2019 | -$9.30 M(-25.3%) | -$2.33 M(-24.4%) | -$9.30 M(+5.1%) |
| Sept 2019 | - | -$3.08 M(+56.5%) | -$8.85 M(+21.2%) |
| June 2019 | - | -$1.97 M(+3.1%) | -$7.30 M(-36.5%) |
| Mar 2019 | - | -$1.91 M(+1.7%) | -$11.50 M(-7.5%) |
| Dec 2018 | -$12.44 M(+1167.4%) | -$1.88 M(+22.1%) | -$12.44 M(+13.2%) |
| Sept 2018 | - | -$1.54 M(-75.1%) | -$10.99 M(+12.6%) |
| June 2018 | - | -$6.17 M(+116.9%) | -$9.76 M(+172.4%) |
| Mar 2018 | - | -$2.85 M(+564.7%) | -$3.58 M(+386.9%) |
| Dec 2017 | -$981.50 K(+331.4%) | -$428.20 K(+39.3%) | -$735.70 K(+139.3%) |
| Sept 2017 | - | -$307.50 K | -$307.50 K |
| Dec 2016 | -$227.50 K | - | - |
FAQ
- What is INmune Bio annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for INmune Bio?
- What is INmune Bio annual EBITDA year-on-year change?
- What is INmune Bio quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for INmune Bio?
- What is INmune Bio quarterly EBITDA year-on-year change?
- What is INmune Bio TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for INmune Bio?
- What is INmune Bio TTM EBITDA year-on-year change?
What is INmune Bio annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INMB is -$29.74 M
What is the all time high annual EBITDA for INmune Bio?
INmune Bio all-time high annual earnings before interest, taxes, depreciation & amortization is -$227.50 K
What is INmune Bio annual EBITDA year-on-year change?
Over the past year, INMB annual earnings before interest, taxes, depreciation & amortization has changed by -$3.79 M (-14.60%)
What is INmune Bio quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INMB is -$12.29 M
What is the all time high quarterly EBITDA for INmune Bio?
INmune Bio all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$307.50 K
What is INmune Bio quarterly EBITDA year-on-year change?
Over the past year, INMB quarterly earnings before interest, taxes, depreciation & amortization has changed by -$3.76 M (-44.07%)
What is INmune Bio TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INMB is -$41.55 M
What is the all time high TTM EBITDA for INmune Bio?
INmune Bio all-time high TTM earnings before interest, taxes, depreciation & amortization is -$307.50 K
What is INmune Bio TTM EBITDA year-on-year change?
Over the past year, INMB TTM earnings before interest, taxes, depreciation & amortization has changed by -$14.54 M (-53.85%)